Although previous studies suggested that the tumorigenicity of mouse double minute 2 (MDM2) was due to its negative regulation of p53, the p53-independent interactions may be equally as important. During recent studies utilizing MDM2 inhibitors, we noted that E2F transcription factor 1 (E2F1) was downregulated upon inhibition of MDM2, regardless of the p53 status of the cancer. The present study investigated the mechanisms responsible for the MDM2-mediated increase in E2F1 expression. MDM2 prolongs the half-life of the E2F1 protein by inhibiting its ubiquitination. MDM2 displaces SCF SKP2 , the E2F1 E3 ligase. Direct binding between MDM2 and E2F1 is necessary for the negative effects of MDM2 on E2F1 ubiquitination, and deletion of the MDM2 nuclear localization signal does not result in loss of the ability to increase the E2F1 protein level. The downregulation of E2F1 upon MDM2 inhibition was not due to either pRB or p14
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Arf . In addition, E2F1 was responsible for at least part of the inhibition of cell proliferation induced by MDM2 knockdown. In conclusion, the present study provides evidence that stabilization of the E2F1 protein is likely another p53-independent component of MDM2-mediated tumorigenesis. More knowledge about theIntroduction Identified more than a decade ago, the mouse double minute 2 (MDM2) oncogene has multiple functions in promoting tumorigenesis (Fakharzadeh et al., 1991; Bond et al., 2005) . Overexpression of the MDM2 protein is present in many human tumors and has been correlated with poor prognosis (Zhang and Wang, 2000; Iwakuma and Lozano, 2003; Rayburn et al., 2005) . Early studies have demonstrated that the tumorigenicity of MDM2 is largely attributed to its negative regulation of tumor suppressor p53.
It is well documented that there is a p53-MDM2 autoregulatory loop (Zhang and Wang, 2000; Bond et al., 2005) . In this loop, the transcription of MDM2 is upregulated via a p53-responsive promoter (P2 promoter). In turn, MDM2 binds to and masks the p53 transcription domain, keeping it functionally inactive (Momand et al., 1992) . Moreover, upon binding to p53, MDM2 shuttles the p53 protein from the nucleus into the cytoplasm, where it facilitates its ubiquitination and subsequent degradation by the proteasome (Chen et al., 1993; Freedman and Levine, 1998; Fuchs et al., 1998; Li et al., 2003) .
However, recent studies have suggested that the p53-independent activities of the oncoprotein may be equally as important. Transgenic mice with the entire MDM2 gene are predisposed to spontaneous tumor formation in a p53 À/À background, and have a high incidence of lymphoma and sarcoma (Jones et al., 1995; Vargas et al., 2003) . Moreover, more than 40 MDM2 variants have been detected in a wide spectrum of human cancers, most of which lack at least part of the p53 binding domain (Bartel et al., 2004) . Some of these variants transform NIH3T3 cells and are associated with high-grade and late-stage human cancers (Liang et al., 2004; Steinman et al., 2004) . Clinical data further emphasize the importance of the p53-independent activities. Although human cancers with both nonfunctional p53 and amplification of MDM2 are rare, the two genetic changes do occur simultaneously in some malignancies that have poorer prognoses compared with those with either abnormality alone (CordonCardo et al., 1994) . To date, it has been demonstrated that MDM2 binds to and modulates several proteins in addition to p53, including p21, pRB, E2F transcription factor 1 (E2F1), ribosomal proteins L5, L11 and L23, PML, NPM, steroid receptors and YY1 (Deb, 2003; Meek and Knippschild, 2003; Zhang et al., 2004a; . Although the biological consequences of these activities are not fully understood, they may be associated with the transforming properties of MDM2.
The oncogenic properties of MDM2 have been demonstrated further in various cell lines, using second-generation anti-MDM2 oligonucleotides (oligo) that inhibit MDM2 expression in tumor cells in vitro and in vivo . These antisense inhibitors have antitumor activity, and chemosensitzation and radiosenstization effects in a variety of tumor models, regardless of p53 status (Wang et al., 1999 (Wang et al., , 2001 (Wang et al., , 2003a Zhang et al., 2003 Zhang et al., , 2004b . However, the mechanisms responsible for the p53-independent tumorigenicity of MDM2 are far from clear. In our previous studies, we also observed E2F1 downregulation in cancer cells without functional p53 following inhibition of MDM2 .
E2F1 was initially identified as a cellular factor necessary for E1A (early region 1A transforming protein of adenovirus) mediating the viral E2 promoter transcription activity (Kovesdi et al., 1986) . It belongs to the E2F transcription factor family, which has six other members (E2F2-E2F7) (Trimarchi and Lees, 2002; Logan et al., 2004) . With the exception of E2F7, these transcription factors regulate gene transcription by forming heterodimers with DP1 and DP2 (Bell and Ryan, 2004) . E2F1 has long been considered oncogenic because of its activity promoting cell cycle progression. When E2F1 dissociates from hyper-phosphorylated RB during the G 0 /early G 1 phase, it activates the transcription of target genes, committing cells in late G 1 phase to initiate cell cycle progression (Bell and Ryan, 2004) . E2F1 has the capability to promote quiescent cells to enter S phase and acts as an oncogene in transforming assays (Bell and Ryan, 2004) . The protein has been shown to be essential for c-Mycinduced carcinogenesis both in vitro and in vivo (Baudino et al., 2003) . Recent clinical studies have shown that E2F1 is correlated with tumor progression and shorter survival time in patients with pancreatic and nonsmall cell lung carcinomas (Gorgoulis et al., 2002; Yamazaki et al., 2003) . The number of known E2F1 target genes has recently been increased using microarray technology, and now includes genes involved in mitosis, chromosome segregation, mitotic spindle checkpoints, DNA repair, chromatin assembly/ condensation, differentiation, embryonic development and apoptosis (Mundle and Saberwal, 2003) . E2F1 induces apoptosis through several p53-dependent and independent mechanisms (La Thangue, 2003) . Since it has so many diverse functions, E2F1 may affect several steps in cancer initiation, growth and progression. There is a need to identify molecules or pathways involved in E2F1 functions. The present study is designed to elucidate the mechanisms of MDM2 upregulation of E2F1, and clarify the role of E2F1 in the response of cancer cells to MDM2 knockdown, independent of p53.
Results

Upregulation of E2F1 by MDM2 results from the inhibition of its ubiquitination
The effects of MDM2 on E2F1 expression were first analysed in PC3 cells either transfected with a pcMV-MDM2 vector (Figure 1a) or treated with an anti-MDM2 antisense oligonucleotide (AS) (Figure 1b) . The level of E2F1 protein increased when MDM2 was overexpressed ( Figure 1a) . As a result of MDM2 inhibition, the E2F1 level decreased dose dependently (Figure 1b) . To further confirm the results, PC3 cells with stable MDM2 knockdown were established, and it was shown that they have a reduced E2F1 protein level compared with parental cells (Figure 1c) . In our previous studies, we found that inhibition of MDM2 results in the downregulation of E2F1 at the protein level but not the mRNA level . To clarify the mechanisms by which MDM2 was able to increase E2F1 expression, PC3 cells were transfected with pcMV-MDM2 or corresponding empty vectors, followed by exposure to the protein synthesis inhibitor cycloheximide (CHX) (10 mg/ml). In PC3 cells with MDM2 overexpression, the half-life of the E2F1 protein was prolonged compared with that in control cells (Figure 2 ).
The E2F1 protein is a substrate of the proteasome, and ubiquitination is essential for its specific degradation. In order to elucidate whether MDM2 affects E2F1 expression through the ubiquitination process, PC3 cells were transfected with different combinations of E2F1, MDM2 and ubiquitin, followed by incubation with the proteasome inhibitor MG132. Compared with cells transfected with E2F1 alone, those with cotransfected ubiquitin had more ubiquitinated E2F1 protein ( Figure 3a ). The ubiquitination of E2F1 was inhibited by overexpression of MDM2 ( Figure 3a ). These results were further confirmed by immunoprecipitation and immunoblotting of purified ubiquitinated E2F1 ( Figure 3b ).
Physical binding of MDM2 displaces E3 Ligase SCF
Skp2 from E2F1
In order to elucidate the mechanisms of inhibition of E2F1 ubiquitination, PC3 cells were used to examine whether there is physical binding between endogenous MDM2 and E2F1 proteins. In immunoprecipitation experiments with endogenous proteins, whole-cell lysates of PC3 cells were precipitated using an MDM2 antibody ( Figure 4Aa ) or E2F1 antibody (Figure 4Ab ), followed by immunoblotting with the E2F1 antibody or MDM2 antibody, demonstrating a direct physical interaction between E2F1 and MDM2. Next, we examined whether MDM2-E2F1 binding was respon- sible for a reduction in E2F1 protein ubiquitination. Several MDM2 deletion constructs that have been described previously (Zhang et al., 2004a) were used to determine which portion of the MDM2 protein was necessary for E2F1 binding. As illustrated in Figure 4 , MDM2 deletion A (aa 1-297) retained the capability of binding to the E2F1 protein, while B (aa 1-179) and C (299-491) did not ( Figure 4Bb) . As a result, deletion A (1-297) had the ability to inhibit E2F1 ubiquitination, while the corresponding empty vector, deletion B or C had no effect (Figure 4Bc ). We further examined whether the binding of MDM2 to E2F1 changes the MDM2 and E2F1 interaction Z Zhang et al conformation of the E2F1 protein to mask its ubiquitin targeting amino acids, or whether it affects the binding of its E3 ligase. As shown in Figure 4Ca , when MDM2 and E2F1 were cotransfected into Cos-7 cells, MDM2 displaced SCF Skp2 , a known E2F1 E3 ligase (Marti et al., 1999) . To confirm that MDM2 competes with SCF Skp2 for binding to E2F1, PC3 cells were first arrested in the G0/G1 phases by serum deprivation for 48 h. At various times after serum release, cell lysates were subjected to immunoprecipation with an E2F1 antibody, and the immunocomplexes were detected by immunoblotting with SCF Skp2 or MDM2 antibody. As shown in Figure  4Cb , during the S/G 2 transition, the binding between E2F1 and MDM2 decreased, while the binding between E2F1 and SCF Skp2 increased in a time-dependent manner. As a result of the competition between MDM2 and SCF Skp2 for E2F1, the E2F1 level increased dramatically when cells in the S phase compared with control and decreased time dependently (Figure 4Cc ). In contrast, in PC3 cells without MDM2, probably due to the absence of the protection of MDM2, there was no detectable increase in E2F1 level at 20 h after serum release, which even decreased further at 24 h ( Figure  4Cd ).
Modulation of E2F1 by MDM2 does not require pRb or p14
Arf Tumor suppressor p14
Arf promotes ubiquitination and proteasomal degradation of E2F1 (Datta et al., 2002) . To exclude the possible involvement of p14
Arf in the regulation effects of MDM2 on E2F1 expression, p53 in MCF-7 cells (without p14 Arf ) was stably knocked down with a siRNA vector. These stable cells were either transfected with MDM2 expression vectors (Figure 5Aa ) or treated with anti-MDM2 AS (Figure 5Ab ). The regulatory effects of MDM2 on E2F1 were observed in cells without p14
Arf ( Figure 5A ), suggesting that the MDM2 stabilization of E2F1 does not require the presence of p14
Arf or p53. Another tumor suppressor, pRb, also modulates E2F1 activities and prolongs the E2F1 half-life (Campanero and Flemington, 1997) . pRb also binds to and modulates the activities of MDM2, promoting p53 ubiquitination and degradation (Hsieh et al., 1999) . According to our previous observations, inhibition of MDM2 in DU145 cells, which have no functional pRb, still resulted in E2F1 downregulation . In order to further confirm these results, DU145 cells were transfected with MDM2. As a result, E2F1 was increased dose-dependently ( Figure 5B ). Based on our observations, pRb and p14
Arf are not required for the effects of MDM2 on E2F1.
MDM2 and E2F1 colocalize in the nucleus
In order to examine whether the localization of these two proteins is important for the effects of MDM2 on E2F1, a mutant MDM2 construct without the nuclear localization signal (NLS) was generated. It was found that MDM2 and E2F1 were colocalized in the nucleus (Figure 6a) , and the mutant MDM2 without the NLS still retained the capability to increase the E2F1 expression although much higher doses of this mutant were needed compared with the dose of wild-type MDM2 in order to achieve the same effect (3 mg) (Figure 6b ).
E2F1 is important to the anti-tumor activities of MDM2 antisense inhibition
In our previous studies, we noted that E2F1 was downregulated accompanying the antitumor activities following MDM2 knockdown by an AS . In the present study, we attempted to clarify the role of E2F1 in the antitumor effects of MDM2 AS. The responses of H1299 parental and E2F1 knockdown cells to the antiMDM2 AS were compared (Figure 7a) . In cell proliferation studies, knockdown of MDM2 resulted in a 66% decrease in proliferation compared to parental cells (Figure 7Ba ). H1299 cells without E2F1 were more sensitive to cell death than the parental cells, as manifested by apoptosis ( Figure 7Bb ) and clonogenic studies (Figure 7Bc ). These observations indicate that E2F1 protects cancer cells from death upon treatment with antisense MDM2 oligo. E2F1 downregulation might be one of the critical mechanisms of action for MDM2 antisense inhibitors. 
Discussion
The MDM2 oncoprotein is overexpressed in a wide variety of human cancers and correlates with poor prognosis, although the mechanisms by which MDM2 promotes carcinogenesis are not fully understood. Initial data indicated that the tumorigenicity of MDM2 could be attributed to its negative regulation of tumor suppressor p53. However, p53-independent oncogenic pathways have recently drawn increasing attention. MDM2 has regulatory or modulatory activity in numerous signaling pathways, and interacts with the androgen receptor (Lin et al., 2002) , insulin like growth factor 1 (Girnita et al., 2003) , TGFb (Sun et al., 1998) and glucocorticoid receptors (Kinyamu and Archer, 2003) . MDM2 also has a role in the regulation of cell cycle-related proteins such as E2F1 (Martin et al., 1995) and p21 (Jin et al., 2003; Zhang et al., 2004a) in tumor angiogenesis and progression by increasing Hypoxia-inducible factor 1 (HIF-1) expression (Bardos et al., 2004) and in the repression of transcription of certain tumor suppressor genes through modification of histone proteins H2A and H2B (Minsky and Oren, 2004) . Likely as a result of inhibition of one or more of these many protumorigenic interactions, our experimental therapeutic data have shown that a novel antisense anti-MDM2 oligonucleotide has antitumor activity in a (Wang et al., 1999 (Wang et al., , 2001 (Wang et al., , 2003a Zhang et al., 2003 Zhang et al., , 2004b . Unfortunately, although the number of proteins identified as interacting with MDM2 has increased rapidly, detailed understanding of MDM2-mediated tumorigenesis in the absence of p53 is incomplete.
In the present study, we have provided another line of evidence of and novel insights into the p53-independent activities of MDM2. Our data indicate that MDM2 has stabilizing effects on the E2F1 protein, independent of p53, based on the following observations: first, there is a positive relationship between the expression levels of MDM2 and E2F1 in PC3 cells, which have no p53; second, MDM2 increases the E2F1 protein half-life; third, MDM2 inhibits the ubiquitination of E2F1 in the absence of p53; fourth, binding of MDM2 displaces the E3 ubiquitin ligase, SCF Skp2 , from E2F1. E2F1 has long been considered an oncoprotein because it has the ability to promote quiescent cells to enter S phase and has transforming capabilities. In previous studies, E2F1 was shown to promote breast cancer cell and hepatocarcinoma cell proliferation, and conferred antiestrogen resistance to breast cancer cells (Arakawa et al., 2004; Louie et al., 2004) . Transgenic models with E2F1 overexpression (Lee et al., 2004) and clinical data from patients with different types of cancer (Gorgoulis et al., 2002; Yamazaki et al., 2003; Imai et al., 2004; Lee et al., 2004; Onda et al., 2004) have further supported the role of E2F1 in oncogenesis. Under normal circumstances, E2F1 gene expression is tightly regulated, and its protein product is rapidly degraded. In contrast, in cells with MDM2 overexpression, the E2F1 protein may be stabilized and kept at a higher level, which may contribute to deregulated proliferation and carcinogenesis. Our hypothesis that the downregulation of E2F1 may be partly responsible for the antitumor effects of MDM2 knockdown is supported by the observation that the proliferation of H1299 parental cells was inhibited by antiMDM2 antisense treatment, while the E2F1 À/À counterparts were resistant. Therefore, our observations have uncovered a previously unidentified mechanism of MDM2 tumorigenicity, which may prove helpful in the understanding of the p53-independent MDM2 tumorigenic activities.
Additionally, the information obtained in the present study may be instrumental in the understanding of E2F1 protein regulation. The diversity of E2F1 functions in many cellular processes makes stringent control of its expression necessary. However, the mechanisms behind this control are largely unknown. It has been shown that (Martin et al., 1995) are very close to those of pRb and p14 Arf , 409-426 and 426-437, respectively (Mundle and Saberwal, 2003) . Therefore, the effects of MDM2 on E2F1 protein stability are likely to affect pRb or p14
Arf binding to E2F1 protein. However, our data seem not to support this hypothesis. In DU145 and MCF-7 cells (with p53 knockdown by siRNA), which lack functional pRb and p14
Arf , respectively, there was still a positive correlation between the expression levels of MDM2 and E2F1. Since the attachment of ubiquitin is an essential step for the specific degradation of a protein by the proteasome, MDM2 might hinder the access of E2F1 protein to either ubiquitin or its E3 ligase, SCF
Skp2
, which catalyses E2F1 ubiquitination. The competition that we have observed between MDM2 and SCF Skp2 for binding to E2F1 at least partially explains how MDM2 inhibits E2F1 ubiquitination. Similar to our results, phosphorylation of Serine-31 by Ataxia Telangiectasia (ATM) kinase or ATM and Rad3-related (ATR) kinase also interferes with SCF Skp2 binding, thereby inhibiting E2F1 degradation (Lin et al., 2001) .
Although the fact that E2F1 can induce apoptosis has been well documented (Stanelle et al., 2005) , E2F1 was recently found to also inhibit apoptosis. In an in vitro study, E2F1 induced Survivin, which is a potent inhibitor of apoptosis (Jiang et al., 2004) . More importantly, Wikonkal et al. observed increased apoptosis of keratinocytes after ultraviolet radiation in E2F1 À/À mice compared with wild-type mice, which was abrogated by ectopically expressed E2F1 in the epidermis (Wikonkal et al., 2003) . These effects were also observed in keratinocytes after g-irradiation. It was suggested that the oncogenicity of E2F1 may, therefore, also be attributed to its ability to inhibit apoptosis, providing another rationale for using MDM2 inhibitors, which also decrease E2F1.
In support of this rationale, the present study has indicated that E2F1 has an important role in cancer therapy, particularly therapies based on MDM2. As a result of the dual roles that E2F1 plays by both promoting carcinogenesis and inducing apoptosis, it is necessary to clarify the functions of E2F1 in cancer cells exposed to treatments based on MDM2 modulation. If upon MDM2 inhibition E2F1's ability to induce apoptosis is decreased, then the anticancer effects would be largely compromised. Fortunately, our data suggest that E2F1 protects cancer cells from cell death induced by antiMDM2 AS, because H1299 cells without E2F1 were more sensitive to treatment. Therefore, downregulation of E2F1 resulting from MDM2 inhibition would result in improved cell killing effects. Our data also provide guidance for future clinical practice targeting MDM2. In order to induce cell death, the inhibition of apoptosis by E2F1 needs to be overcome. Downregulation of E2F1 expression induced by MDM2 knockdown may be one of the possible routs. Moreover, considering the protective role of E2F1, there might be synergistic effects upon combining treatments to target both MDM2 and E2F1.
In conclusion, the present study has significance both in cancer biology and for the development of novel therapies against human cancers. Our observations provide new insights into the p53-independent mechanisms of MDM2-induced oncogenesis, and also clarify the roles of E2F1 downregulation in the antitumor activities induced by MDM2 knockdown. Based on our observations, combined targeting of MDM2 and E2F1 might be an effective novel therapy against human cancers, regardless of the status of p53.
Materials and methods
Plasmids and reagents
The pCMV-MDM2 and the pcDNA3-Flag-MDM2 vectors for expression of human MDM2 were kindly provided by Dr Jiandong Chen (Moffitt Cancer Center) and Dr Ze'ev Ronai (Ruttenberg Cancer Center), respectively. Additional constructs expressing deletions of MDM2 protein were generated by proof-reading PCR of pCMV-MDM2 using primers containing BamHI and NotI sites followed by ligation back into the same enzymes digested pcDNA3-Flag-MDM2. The E2F1-HA and SCF Skp2 vectors were kindly provided by Dr E Flemington (Tulane) and Dr Pagano M (NYU), respectively. pcDNA3-Ub vector was a gift from Dr Bert O'Malley (Baylor). To construct Short Interfering RNA (siRNA) expression plasmids under the control of U6 promoter, selected oligo were cloned into pBabe-U6 at BamHI and XhoI sites for expression of siRNA in vivo. One pair of siRNA oligo from p53 was synthesized and cloned into pBabe-U6. The target sequence of the oligo for p53 knockdown (derived from the p53 gene) is 5 0 -GACTCCAGTGGTAATCTAC. The MDM2 knockdown siRNA construct was described previously (Zhang et al., 2004a) . Puromycin, CHX and MG132 were purchased from Sigma (St Louis, MO, USA). The antihuman-MDM2 AS and its control oligo were described previously .
Cell lines
PC3 and DU145 cells were maintained as described previously . Cos-7 cells were cultured in Dulbecco's modification of Eagle's medium containing 10% FBS and 1% penicillin/streptomycin. PC3 cells with MDM2 knockdown were described previously (Zhang et al., 2004a) and H1299 cells with E2F1 deletion by siRNA were kindly provided by Dr WD Cress (Moffitt Cancer Center). To establish the p53 stable knockdown MCF-7 cell line, MCF-7 cells were transfected with pBabe-U6-p53. Positive cell clones were selected, maintained by puromycin (0.5 mg/ml), and confirmed by immunoblotting.
Co-immunoprecipitation
The procedures of co-immunoprecipitation have been described previously (Zhang et al., 2004a) . In brief, cells were lysed in buffer containing 137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% NP40, 20 mM Tris, pH 8.0 and 5% (v/v) protease inhibitors cocktail (Sigma). The extracts were incubated with antibodies indicated in the figures at 41C overnight. The immunocomplex was captured by protein G-sepharose beads (Amersham), which were washed three times with lysis buffer. The bound proteins were eluted by 5 Â SDS sample buffer at 1001C for 5 min, resolved on SDS-PAGE and detected by the appropriate antibodies indicated in the figures.
Ubiquitination assay
Cell lysates were immunoprecipated with polyclonal E2F1 antibody (Santa Cruz) and the bound proteins were purified with protein G-sepharose beads, resolved on SDS-PAGE and detected by Ub antibody (Santa Cruz).
Immunofluorescence PC3 cells were grown on coverslips for 24 h. After fixation with 3% formaldehyde, cells were permeabilized with 0.5% Triton X-100 followed by blocking in 3% BSA for 15 min. Then the cells were sequentially incubated with mouse MDM2 antibody, goat anti-mouse IgG AlexaFluor-488 (Molecular probes), and rabbit E2F1 antibody, goat anti-rabbit IgG AlexaFluor-594 (Molecular probes). After every round of incubation with antibody, cells were washed in PBS 4 times each for 5 min. Finally the coverslips were washed, counter stained with Hoechst 33258 for 4 min and mounted in 0.2% npropyl gallate. Immunofluorescence images were captured by confocal microscopy.
Apoptosis and BrdU cell proliferation assay
The methods utilized have been described previously .
Clonogenic assay
Cells were treated with MDM2 antisense ologonucleotides at different concentrations for 24 h. After being rinsed with fresh medium, cells were allowed to grow for 10-14 days to form colonies, which were stained with Crystal Violet (0.4 g/l) (Sigma).
Cell cycle distribution assay
Cells were trypsinized, washed with PBS and fixed in 1.5 ml 95% ethanol at 41C overnight, then incubated with RNAse and stained by propidium iodide (Sigma). DNA contents were determined by flow cytometry. Abbreviations MDM2, mouse double minute 2; Oligo, oligonucleotides; AS, antisense oligonucleotide; ASM, mismatch control oligonucleotide; E2F1, E2F transcription factor 1.
